肝内胆管细胞癌肿瘤标志物研究与临床应用进展

doi:10.6040/j.issn.1671-7554.0.2018.1011

摘要/Abstract

摘要： 肝内胆管细胞癌(ICC)是仅次于肝细胞癌的第二大肝脏恶性肿瘤,且发病率呈逐年上升趋势。ICC早期症状较隐匿、进展快、恶性程度高、预后较差。早诊断、早治疗可有效改善ICC患者的生存水平。通过检测ICC患者组织及外周血清肿瘤标志物,深入开展ICC发生、发展、复发与转移相关研究,对于阐明ICC发病机制以及研究新的ICC早期诊断与治疗方法,具有重要的研究意义和应用价值。

关键词: 肝内胆管细胞癌, 肿瘤标志物, 诊断, 预后

Abstract: Intrahepatic cholangiocarcinoma(ICC)is the second most common primary liver tumor with increasing incidence worldwide. The early symptoms are insidious. With rapid progression and high malignancy, the tumor shows poor 山东大学学报 (医学版)56卷10期 -高春芳,等.肝内胆管细胞癌肿瘤标志物研究与临床应用进展 \=-outcomes. Early diagnosis and treatment can effectively improve patients’ survival. Detection of the cancer biomarkers is conducive not only for related studies on the genesis, development and recurrence of ICC, but also for its diagnosis and treatment.

Key words: Intrahepatic cholangiocarcinoma, Cancer biomarkers, Diagnosis, Prognosis

中图分类号:

R574

高春芳,黄晨军. 肝内胆管细胞癌肿瘤标志物研究与临床应用进展[J]. 山东大学学报 (医学版), 2018, 56(10): 24-30.

GAO Chunfang, HUANG Chenjun. Cancer biomarkers of intrahepatic cholangiocarcinoma and the clinical application[J]. Journal of Shandong University (Health Sciences), 2018, 56(10): 24-30.

参考文献

[1] Esnaola NF, Meyer JE, Karachristos A, et al. Evaluation and management of intrahepatic and extrahepatic cholangiocarcinoma[J]. Cancer, 2016, 122(9): 1349-1369.
[2] Banales JM, Cardinale V, Carpino G, et al. Expert consensus document: Cholangiocarcinoma: current knowledge and future perspectives consensus statement from the European Network for the Study of Cholangiocarcinoma(ENS- CCA)[J]. Nat Rev Gastroenterol Hepatol, 2016, 13(5): 261-280.
[3] Lafaro KJ, Cosgrove D, Geschwind JF, et al. Multidisciplinary care of patients with intra- hepatic cholangiocarcinoma: updates in management[J]. Gastroenterol Res Pract, 2015, 2015: 860861. doi: 10.1155/2015/860861.
[4] Zhu AX, Borger DR, Kim Y, et al. Genomic profiling of intrahepatic cholangiocarcinoma: refining prognosis and identifying therapeutic targets[J]. Ann Surg Oncol, 2014, 21(12): 3827-3834.
[5] 黄禾, 刘晓蓉, 尤启冬. 异柠檬酸脱氢酶及其突变体抑制剂在急性髓系白血病治疗领域的研究进展[J].药学进展, 2018, 42(3): 207-213. HUANG He, LIU Xiaorong, YOU Qidong.Advances in isocitrate dehydrogenase and the inhibitors of its mutants for acute myeloid leukemia[J]. Progress in Pharmaceutical Sciences, 2018, 42(3): 207-213.
[6] Grassian AR, Pagliarini R, Chiang DY, et al. Mutations of isocitrate dehydrogenase 1 and 2 in intrahepatic cholangiocarcinoma[J]. Curr Opin Gastroenterol, 2014, 30(3): 295-302.
[7] Wang P, Dong Q, Zhang C, et al. Mutations in isocitrate dehydrogenase 1 and 2 occur frequently in intrahepatic cholangiocarcinomas and share hypermethylation targets with glioblastomas[J]. Oncogene, 2013, 32(25): 3091-3100.
[8] Jiao Y, Pawlik TM, Anders RA, et al. Exome sequencing identifies frequent inactivating mutations in BAP1, ARID1A and PBRM1 in intrahepatic cholangiocarcinomas[J]. Nat Genet, 2013, 45(12): 1470-1473.
[9] Grassian AR, Pagliarini R, Chiang D, et al. Mutations of isocitrate dehydrogenase 1 and 2 in intrahepatic cholangiocarcinoma[J]. Curr Opin Gastroenterol, 2014, 30(3): 295-302.
[10] Ostrem JM, Peters U, Sos ML, et al. K-Ras(G12C)inhibitors allosterically control GTP affinity and effector interactions[J]. Nature, 2013, 503(7477): 548-551.
[11] Krasinskas AM, Moser A, Saka B, et al. KRAS mutant allele-specific imbalance is associated with worse prognosis in pancreatic cancer and progression to undifferentiated carcinoma of the pancreas[J]. Mod Pathol, 2013, 26(10): 1346-1354.
[12] Xu RF, Sun JP, Zhang SR, et al. KRAS and PIK3CA but not BRAF genes are frequently mutated in Chinese cholangiocarcinoma patients[J]. Biomed Pharmacother, 2011, 65(1): 22-26.
[13] Tannapfel A, Benicke M, Katalinic A, et al. Frequency of p16(INK4A)alterations and K-ras mutations in intrahepatic cholangiocarcinoma of the liver[J]. Gut, 2000, 47(5): 721-727.
[14] Kennedy L, Baker K, Hodges K, et al. Dysregu- lation of vitamin D3 synthesis leads to enhanced cholangiocarcinoma growth[J]. Dig Liver Dis, 2013, 45(4): 316-322.
[15] Zheng T, Hong X, Wang J, et al. Gankyrin promotes tumor growth and metastasis through activation of IL-6/STAT3 signaling in human cholangiocarcinoma[J]. Hepatology, 2014, 59(3): 935-946.
[16] Morris SM, Baek JY, Koszarek A, et al. Transforming growth factor-beta signaling promotes hepatocarcinogenesis induced by p53 loss[J]. Hepatology, 2012, 55(1): 121-131.
[17] O'Dell MR, Huang JL, Whitney-Miller CL, et al. Kras(G12D)and p53 mutation cause primary intrahepatic cholangiocarcinoma[J]. Cancer Res, 2012, 72(6): 1557-1567.
[18] Luo G, Li B, Duan C, et al. c-Myc promotes cholangiocarcinoma cells to overcome contact inhibition via the mTOR pathway[J]. Oncol Rep, 2017, 38(4): 2498-2506.
[19] Songserm N, Promthet S, Sithithaworn P, et al. Risk factors for cholangiocarcinoma in high-risk area of Thailand: role of lifestyle, diet and methylenetetrahydrofolate reductase polymor- phisms[J]. Cancer Epidemiol, 2012, 36(2): e89-94.
[20] Khoontawad J, Pairojkul C, Rucksaken R, et al. Differential protein expression marks the transition from infection with to cholangiocar- cinoma[J]. Mol Cell Proteomics, 2017, 16(5): 911-923.
[21] Singh S, Tang SJ, Sreenarasimhaiah J, et al. The clinical utility and limitations of serum carbohydrate antigen(CA19-9)as a diagnostic tool for pancreatic cancer and cholangiocarcinoma[J]. Dig Dis Sci, 2011, 56(8): 2491-2496.
[22] Viterbo D, Gausman V, Gonda T, et al. Diagnostic and therapeutic biomarkers in pancreaticobiliary malignancy[J]. World J Gastrointest Endosc, 2016, 8(3): 128-142.
[23] Razumilava N, Gores GJ. Cholangiocarcinoma[J]. Lancet, 2014, 383(9935): 2168-2179.
[24] Chalasani N, Baluyut A, Ismail A, et al. Cholangiocarcinoma in patients with primary sclerosing cholangitis: a multicenter case-control study[J]. Hepatology, 2000, 31(1): 7-11.
[25] Shen WF, Zhong W, Xu F, et al. Clinicopatho-logical and prognosticanalysis of 429 patients with intrahepatic cholangiocarcinoma[J]. World J Gastroenterol, 2009, 15(47): 5976-5982.
[26] 徐靖, 易炜, 万百顺. MMP-2和MMP-9在肝内胆管细胞癌组织中的表达及意义[J]. 中国普通外科杂志, 2015, 24(8): 1107-1111. XU Jing, YI Wei, WAN Baishun, etal.MMP-2 and MMP-9 expressions in intrahepatic cholangiocarcinoma tissue and the significance[J] Chinese Journal of General Surgery, 2015, 24(8): 1107-1111.
[27] Hirashita T, Iwashita Y, Ohta M, et al. Expression of matrix metalloproteinase-7 is an unfavorable prognostic factor in intrahepatic cholangiocarcinoma[J]. J Gastrointest Surg, 2012, 16(4): 842-848.
[28] Sun Q, Zhao CZ, Xia LZ, et al. High expression of matrix metalloproteinase-9 indicates poor prognosis in human hilar cholangiocarci- noma[J]. Int J Clin Exp Pathol, 2014, 7(9): 6157-6164.
[29] Tongtawee T, Kaewpitoon SJ, Loyd R, et al. High expression of matrix metalloproteinase-11 indicates poor prognosis in human cholangiocar-cinoma[J]. Asian Pac J Cancer Prev, 2015, 16(9): 3697-3701.
[30] Jo Chae K, Rha SY, Oh BK, et al. Expression of matrix metalloproteinase-2 and -9 and tissueinhibitor of metalloproteinase-1 and -2 in intraductal and nonintraductalgrowthtype of cholangiocarcinoma[J]. Am J Gastroenterol, 2004, 99(1): 68-75.
[31] Zhang FH, Ren HY, Shen JX, et al. Magnolol suppresses the proliferation and invasion of cholangiocarcinoma cells via inhibiting the NF-κB signaling pathway[J]. Biomed Pharmacother, 2017, 94: 474-480. doi:10.1016/j.biopha.2017.07.085.
[32] 张欣, 史若愚, 樊嘉. Dickkopf-1在肝内胆管细胞癌组织及血清中的表达及其临床意义[J].中国临床医学, 2012, 19(2): 102-104.
[33] Shen QJ, Fan J, Yang XR, et al. Serum DKK1 as a protein biomarker for the diagnosis of hepatocellular carcinoma: a large-scale, multice-ntre study[J]. Lancet Oncol, 2012, 13(8): 817-826.
[34] Shi RY, Yang XR, Shen QJ, et al. High expression of Dickkopf-related protein 1 is related to lymphatic metastasis and indicates poor prognosis in intrahepatic cholangiocar- cinoma patients after surgery[J]. Cancer, 2013, 119(5): 993-1003.
[35] McGoughIan J, Vincent JP. Exosomes in developmental signalling[J]. Development, 2016, 143(14): 2482-2493.
[36] Arbelaiz A, Azkargorta M, Krawczyk M, et al. Serum extracellular vesicles contain protein biomarkers for primary sclerosing cholangitis and cholangiocarcinoma[J]. Hepatology, 2017, 66(4): 1125-1143.
[37] Clapéron A, Mergey M, Nguyen HB, et al. EGF/EGFR axis contributes to the progression of cholangiocarcinoma through the induction of an epithelial-mesenchymal transition[J]. J Hepatol, 2014, 61(2): 325-332.
[38] Sasaki M, Matsubara T, Yoneda N, et al. Overexpression of enhancer of zeste homolog 2 and MUC1 may be related to malignant behaviour in intraductal papillary neoplasm of the bile duct[J]. Histopathology, 2013, 62(3): 446-457.
[39] Hoshino A, Costa-Silva B, Shen TL, et al. Tumour exosome integrins determine organo- tropic metastasis[J]. Nature, 2015, 527(7578): 329-335.
[40] Yamada D, Rizvi S, Razumilava N, et al. IL-33 facilitates oncogene-induced cholangiocarcino- ma in mice by an interleukin-6-sensitive mechanism[J]. Hepatology, 2015, 61(5): 1627-1642.
[41] Sulpice L, Rayar M, Desille M, et al. Molecular profiling of stroma identifies osteopontin as an independent predictor of poor prognosis in intrahepatic cholangiocarcinoma[J]. Hepatology, 2013, 58(6): 1992-2000.
[42] Lee CT, Wu TT, Lohse CM, et al. High-mobility group AT-hook 2: an independent marker of poor prognosis in intrahepatic cholangiocarcinoma[J]. Hum Pathol, 2014, 45(11): 2334-2340.
[43] Huang L, ChenW, Liang P, et al. Serum CYFRA 21-1 in biliary tract cancers: a reliable biomarker for gallbladder carcinoma and intrahepatic cholangiocarcinoma[J]. Dig Dis Sci, 2015, 60(5): 1273-1283.
[44] Lau KS, Dennis JW. N-Glycans in cancer progression[J]. Glycobiology, 2008, 18(10): 750-760.
[45] Matsuda A, KunoAtsushi,Kawamoto Toru,et al. Wisteria floribunda agglutinin-positive mucin 1 is a sensitive biliary marker for human cholangiocarcinoma[J]. Hepatology, 2010, 52(1): 174-182.
[46] Matsuda A, Kuno A, Matsuzaki H, et al. Glycoproteomics-based cancer marker discovery adopting dual enrichment with Wisteria floribunda agglutinin for high specific glyco-diagnosis of cholangiocarcinoma[J]. J Proteomics, 2013, 85: 1-11. doi: 10.1016/j.jprot.2013.04.017.
[47] Indramanee S, Silsirivanit A, Pairojkul C, et al. Aberrant glycosylation in cholangiocarcinoma demonstrated by lectin-histochemistry[J]. Asian Pac J Cancer Prev, 2012, 13(Suppl): 119-124.
[48] Saentaweesuk W, Silsirivanit A, Vaeteewoottacharn K, et al. Clinical significance of GalNAcylated glycans in cholangiocarcinoma: Values for diagnosis and prognosis[J]. Clin Chim Acta, 2018, 477: 66-71. doi: 10.1016/j.cca.2017.12.005.

多维度评价

Viewed

Full text

Abstract

Cited

Shared

Discussed